Company intelligence / Profile preview

Nicoya Health

Houston, Texas, United States

Ownership: Private
Development stage: Other

Overview

Nicoya Health’s lead program, an autologous expanded regulatory T cell therapy for amyotrophic lateral sclerosis, demonstrated safety and tolerability in a phase 1 trial with signals suggesting potential slowing or halting of disease progression; these programs and platforms were merged into Coya Therapeutics in 2021.[1]

Therapeutic areas: ImmunologyNeurology
Modalities: Cell therapyExosome-based therapySmall molecule
Industry: Biotech

Partnerships

Houston Methodist Neurological Institute

Beyond the preview

Go deeper on Nicoya Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicoya Health.

Explore the full profile